Pneumococcal responses are similar in Papua New Guinean children aged 3-5 years vaccinated in infancy with pneumococcal polysaccharide vaccine with or without prior pneumococcal conjugate vaccine, or without pneumococcal vaccination

被引:3
|
作者
van den Biggelaar, Anita H. J. [1 ]
Richmond, Peter C. [2 ]
Fuery, Angela [2 ,5 ]
Anderson, Denise [1 ]
Opa, Christine [3 ]
Saleu, Gerard [3 ]
Lai, Mildred [3 ]
Francis, Jacinta P. [3 ]
Alpers, Michael P. [4 ]
Pomat, William S. [3 ]
Lehmann, Deborah [1 ]
机构
[1] Univ Western Australia, Telethon Kids Inst, Perth, WA, Australia
[2] Univ Western Australia, Sch Paediat & Child Hlth, Perth, WA, Australia
[3] Papua New Guinea Inst Med Res, Goroka, Eastern Highlan, Papua N Guinea
[4] Curtin Univ, Sch Hlth Sci, Int Hlth, Perth, WA, Australia
[5] Baylor Coll Med, Houston, TX 77030 USA
来源
PLOS ONE | 2017年 / 12卷 / 10期
基金
英国医学研究理事会; 英国惠康基金; 澳大利亚国家健康与医学研究理事会;
关键词
RESPIRATORY-TRACT INFECTIONS; STREPTOCOCCUS-PNEUMONIAE; IMMUNE-RESPONSE; HYPORESPONSIVENESS; IMMUNOGENICITY; DISEASE; PERSISTENCE; 7-VALENT; EFFICACY; BOOSTER;
D O I
10.1371/journal.pone.0185877
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Trial design In an earlier trial, Papua New Guinean (PNG) children at high risk of pneumococcal disease were randomized to receive 0 or 3 doses of 7-valent pneumococcal conjugate vaccine (PCV7), followed by a single dose of 23-valent pneumococcal polysaccharide vaccine (PPV23) at 9 months of age. We here studied in a non-randomized follow-up trial the persistence of pneumococcal immunity in these children at 3-5 years of age (n = 132), and in 121 community controls of a similar age with no prior pneumococcal vaccination. Methods Circulating IgG antibody titers to all PCV7 and PPV23-only serotypes 2, 5 and 7F were measured before and after challenge with 1/5 th of a normal PPV23 dose. Serotype-specific memory B-cells were enumerated at 10 months and 3-5 years of age for a subgroup of study children. Results Serotype-specific IgG antibody titers before and after challenge were similar for children who received PCV7/PPV23, PPV23 only, or no pneumococcal vaccines. Before challenge, at least 89% and 59% of children in all groups had serotype-specific titers similar to 0.35 mu g/ml and similar to 1.0 mu g/ml, respectively. Post-challenge antibody titers were higher or similar to pre-challenge titers for most children independent of pneumococcal vaccination history. The rise in antibody titers was significantly lower when pre-challenge titers were higher. Overall the relative number of serotype-specific memory B-cells remained the same or increased between 10 months and 3-5 years of age, and there were no differences in serotype-specific memory B-cell numbers at 3-5 years of age between the three groups. Conclusions Immunity induced by PCV7 and/or PPV23 immunization in infancy does not exceed that of naturally acquired immunity in 3-5-year-old children living in a highly endemic area. Also, there was no evidence that PPV23 immunization in the first year of life following PCV7 priming induces longer-term hypo-responsiveness.
引用
收藏
页数:18
相关论文
共 50 条
  • [21] Immunogenicity and safety of 23-valent pneumococcal polysaccharide vaccine as a booster dose in 12-to 18-month-old children primed with 3 doses of 7-valent pneumococcal conjugate vaccine
    Thisyakorn, Usa
    Chokephaibulkit, Kulkanya
    Kosalaraksa, Pope
    Benjaponpitak, Suwat
    Pancharoen, Chitsanu
    Chuenkitmongkol, Sunate
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2014, 10 (07) : 1859 - 1865
  • [22] Invasive pneumococcal disease among children younger than 5 years of age before and after introduction of pneumococcal conjugate vaccine in Casablanca, Morocco
    Diawara, Idrissa
    Zerouali, Khalid
    Katfy, Khalid
    Zaki, Bahija
    Belabbes, Houria
    Najib, Jillali
    Elmdaghri, Naima
    INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2015, 40 : 95 - 101
  • [23] Use of 13-Valent Pneumococcal Conjugate Vaccine and 23-Valent Pneumococcal Polysaccharide Vaccine Among Adults Aged ≥65 Years: Updated Recommendations of the Advisory Committee on Immunization Practices
    Matanock, Almea
    Lee, Grace
    Gierke, Ryan
    Kobayashi, Miwako
    Leidner, Andrew
    Pilishvili, Tamara
    MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT, 2019, 68 (46): : 1069 - 1075
  • [24] Use of 13-Valent Pneumococcal Conjugate Vaccine and 23-Valent Pneumococcal Polysaccharide Vaccine Among Adults Aged ≥65 Years: Recommendations of the Advisory Committee on Immunization Practices (ACIP)
    Tomczyk, Sara
    Bennett, Nancy M.
    Stoecker, Charles
    Gierke, Ryan
    Moore, Matthew R.
    Whitney, Cynthia G.
    Hadler, Stephen
    Pilishvili, Tamara
    MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT, 2014, 63 (37): : 822 - 825
  • [25] Effect of 10-Valent Pneumococcal Conjugate Vaccine on Streptococcus pneumoniae Nasopharyngeal Carriage Among Children Less Than 5 Years Old: 3 Years Post-10-Valent Pneumococcal Conjugate Vaccine Introduction in Mozambique
    Valenciano, Sandra J.
    Moiane, Benild
    Lessa, Fernanda C.
    Chauque, Alberto
    Massora, Sergio
    Pimenta, Fabiana C.
    Mucavele, Helio
    Verani, Jennifer R.
    Carvalho, Maria da Gloria
    Whitney, Cynthia G.
    Tembe, Nelson
    Sigauque, Betuel
    JOURNAL OF THE PEDIATRIC INFECTIOUS DISEASES SOCIETY, 2021, 10 (04) : 448 - 456
  • [26] Re-emergence of pneumococcal colonization by vaccine serotype 19F in persons aged ≥5 years after 13-valent pneumococcal conjugate vaccine introduction-Alaska, 2008-2013
    Gounder, Prabhu P.
    Bruden, Dana
    Rudolph, Karen
    Zulz, Tammy
    Hurlburt, Debby
    Thompson, Gail
    Bruce, Michael G.
    Hennessy, Thomas W.
    VACCINE, 2018, 36 (05) : 691 - 697
  • [27] Increase in incidence of invasive pneumococcal disease caused by serotype 3 in children eight years after the introduction of the pneumococcal conjugate vaccine in Hong Kong
    Ho, Pak-Leung
    Law, Pierra Ying-Tung
    Chiu, Susan S.
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2019, 15 (02) : 455 - 458
  • [28] Pneumococcal Conjugate Vaccine Protection against Coronavirus-Associated Pneumonia Hospitalization in Children Living with and without HIV
    Nunes, Marta C.
    Cutland, Clare L.
    Klugman, Keith P.
    Madhi, Shabir A.
    MBIO, 2021, 12 (01): : 1 - 11
  • [29] A phase 3 study of safety and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, followed by 23-valent pneumococcal polysaccharide vaccine, in children with HIV
    Wilck, Marissa
    Barnabas, Shaun
    Chokephaibulkit, Kulkanya
    Violari, Avy
    Kosalaraksa, Pope
    Yesypenko, Svitlana
    Chukhalova, Iryna
    Dagan, Ron
    Richmond, Peter
    Mikviman, Elena
    Morgan, Leslie
    Feemster, Kristen
    Lupinacci, Robert
    Chiarappa, Joseph A.
    Madhi, Shabir
    Bickham, Kara
    Musey, Luwy
    AIDS, 2023, 37 (08) : 1227 - 1237
  • [30] The Immunogenicity of 7-Valent Pneumococcal Conjugate Vaccine versus 23-Valent Polysaccharide Vaccine in Adults Aged 50-80 Years
    Goldblatt, David
    Southern, Jo
    Andrews, Nick
    Ashton, Lindsey
    Burbidge, Polly
    Woodgate, Sarah
    Pebody, Richard
    Miller, Elizabeth
    CLINICAL INFECTIOUS DISEASES, 2009, 49 (09) : 1318 - 1325